Targeting YTHDF2 to inhibit its expression can enlarge hematopoietic stem cells, enhance bone marrow reconstruction, and selectively impair AML [53–55], suggesting that it may be useful in the treatment of hematological malignant tumors. The gene discussed is YTHDF2; the disease is acute myeloid leukemia.